CION Ameerpet
Modern lymphoma treatment is built on more than a microscope. Molecular and genetic tests read the biology of your lymphoma — cell of origin in DLBCL, double-hit rearrangements, and markers like CD20 — to pin down the exact subtype. Here's what each test means and how CION uses it.
When lymphoma is diagnosed, the pathologist first looks at the biopsy under a microscope. But two lymphomas that look almost identical can behave very differently — and that difference lies in their biology. Molecular and genetic testing reads that biology directly: the proteins on the surface of the cells, the pattern of genes that are active, and specific genetic rearrangements inside the tumour. These are the details that turn "a lymphoma" into a precise, named subtype.
All of these tests are run on the same tissue used to make the diagnosis, using techniques such as immunohistochemistry, flow cytometry and FISH. The results do three things: they confirm the exact subtype, they reveal prognostic features such as cell of origin, and they flag high-risk biology such as a "double-hit" rearrangement. Together this fingerprint guides how intensively the lymphoma should be treated. It is a standard part of a modern work-up recommended by NCCN and ESMO.
This page focuses on the testing itself — what it measures and why it matters. For the wider picture, see the Lymphoma hub, and for treatment options see Lymphoma Treatment in Hyderabad. If you already hold a pathology report, our team can review it — book a free consultation.
The 2016 revision of the World Health Organization classification of lymphoid tumours — and its 2022 update — made genetics part of the diagnosis itself, not just an added detail. Categories such as "high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements" (double-hit lymphoma) are now defined by their genetics, which is why FISH testing on the biopsy tissue is recommended. In other words, the molecular test, not the microscope alone, now names the disease. (Source: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, as referenced in NCCN and ESMO lymphoma guidelines.)
Different techniques answer different questions. Your pathologist chooses the panel based on the suspected subtype and how the cells look. Here are the four you are most likely to see mentioned on a report.
Stains the tissue to reveal which proteins the cells carry — for example CD20, CD3, CD30, CD10, BCL6 and MUM1. This is the backbone of subtyping and the usual way cell of origin is worked out in DLBCL. Read more on our immunohistochemistry page.
Analyses cells in a fluid sample (blood, marrow or a node) and measures many surface markers at once, rapidly. It is especially useful for distinguishing B-cell from T-cell lymphomas and for detecting circulating disease. See flow cytometry & immunophenotyping.
Fluorescence in-situ hybridisation looks for specific genetic breaks — most importantly MYC, BCL2 and BCL6. This is the test that identifies a double-hit / high-grade B-cell lymphoma, which changes treatment intensity.
Measures which genes are switched on across the tumour. In DLBCL it is the reference method for assigning cell of origin — germinal-centre (GCB) versus activated B-cell (ABC/non-GCB) — though in routine practice an IHC algorithm is often used as a practical stand-in.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just been diagnosed, unsure whether cell-of-origin or double-hit testing has been done, or want your molecular report explained before treatment? CION's haemato-oncology team is here.
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma, and it is not one single disease. Gene-expression studies showed that DLBCL falls into groups based on which stage of a normal B-cell the tumour most resembles — its cell of origin. The two main groups are germinal-centre B-cell (GCB) and activated B-cell (ABC), also called non-GCB.
Why does it matter? Because the two groups tend to behave differently, cell of origin is a recognised prognostic feature and appears on many DLBCL pathology reports. In everyday practice it is usually assigned using an immunohistochemistry algorithm — a panel of markers such as CD10, BCL6 and MUM1 read through a set of rules (the Hans algorithm is the best known) — because gene-expression profiling is not available everywhere. Working out cell of origin is one piece of the larger question of how doctors identify which lymphoma subtype you have.
Cell of origin is one input among several. It is always read alongside stage, LDH, and other features by the tumour board — never used in isolation to decide care.
A double-hit (or triple-hit) lymphoma carries a rearrangement of the MYC gene together with a rearrangement of BCL2 and/or BCL6. It is now recognised as high-grade B-cell lymphoma with these rearrangements — an aggressive category that is treated more intensively. The only way to find it is FISH on the biopsy, which is why NCCN recommends FISH for MYC, and for BCL2 and BCL6, in large B-cell lymphomas. Here are the markers you are most likely to see explained on a report.
| Marker | What it is | Why it's tested |
|---|---|---|
| CD20 | Surface protein on most B-cells | Confirms a B-cell lymphoma; makes the lymphoma suitable for anti-CD20 antibody therapy (route to treatment) |
| CD3 | Surface protein on T-cells | Helps separate T-cell from B-cell lymphomas |
| CD30 / CD15 | Surface proteins | Important in classifying Hodgkin lymphoma and some T-cell lymphomas |
| CD10, BCL6, MUM1 | Panel of markers | Used together to assign cell of origin (GCB vs non-GCB) in DLBCL |
| MYC, BCL2, BCL6 | Gene rearrangements (FISH) | Identify double-hit / high-grade B-cell lymphoma |
| Ki-67 | Proliferation marker | Shows how fast the lymphoma cells are dividing |
Markers and their interpretation vary by individual and by subtype; this table is a general guide. The panel is always chosen by the pathologist, and results are interpreted together, not in isolation. Testing follows NCCN and ESMO guidance.
Molecular and genetic tests are only as good as the sample they run on. A full marker panel plus FISH needs an adequate amount of well-preserved tissue, which is why lymphoma is best diagnosed on a whole lymph node rather than a tiny fragment.
A fine-needle aspirate alone rarely provides enough for molecular testing. At CION the biopsy is coordinated so the right tissue is collected the first time — sparing you a repeat procedure. Your finished report, with all its markers, is explained in the lymphoma pathology report guide.
Lymphomas are among the more treatable cancers, and getting the molecular subtype right is part of why. Published series report that Hodgkin lymphoma has around an 80–90% five-year survival, and diffuse large B-cell lymphoma around 60–70%, with figures continuing to improve as testing and therapy advance. These are averages from large datasets — individual outlook varies with subtype, stage, molecular features and overall health, so your own figures should come from your treating team. (Source: published survival series referenced in NCCN and ESMO lymphoma guidelines; figures vary by individual.)
Once the markers and genetics are back, the results are brought together to shape the plan. CION delivers the testing, the systemic (drug) therapy, radiation and follow-up directly, and coordinates any specialist referrals. In broad terms:
The marker pattern turns a broad diagnosis into a precise, named lymphoma — for example separating a B-cell from a T-cell lymphoma, or Hodgkin from non-Hodgkin. This is the foundation everything else is built on, and is covered further in how your subtype is identified.
Certain markers point to a class of therapy. A CD20-positive B-cell lymphoma, for instance, is suitable for an anti-CD20 monoclonal antibody combined with chemotherapy — we describe treatment by mechanism here, and the specific regimens are set out on the Lymphoma Treatment page.
High-risk biology — such as a double-hit rearrangement — usually calls for a more intensive approach, while more favourable features may allow a standard plan. The tumour board weighs the molecular result against stage, LDH and your overall health before deciding.
No single marker decides your care. Every result is discussed by CION's multidisciplinary team so the plan reflects the whole picture — this is why a molecular report should always be read by specialists, not interpreted alone. To have yours reviewed, choose the Best Lymphoma Hospital in Hyderabad team or one of our Best Lymphoma Doctors in Hyderabad.
Molecular results carry a lot of weight, so a second opinion is especially worthwhile in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's haemato-oncology tumour board — especially valuable if cell-of-origin or double-hit testing has not yet been arranged on your biopsy.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Molecular and genetic testing looks beyond how lymphoma cells appear under the microscope to read the biology of the tumour itself — the proteins on the cell surface, the genes that are switched on, and specific genetic rearrangements. It is done on the same biopsy tissue used to make the diagnosis, using techniques such as immunohistochemistry, flow cytometry, FISH and gene-expression profiling. The results refine the exact lymphoma subtype, identify features like cell of origin or a "double-hit" rearrangement, and guide how intensively the disease should be treated. These tests are a standard part of a modern lymphoma work-up, in line with NCCN and ESMO guidance, and are arranged directly at CION on your pathology sample.
Cell of origin describes which stage of a normal B-cell your diffuse large B-cell lymphoma (DLBCL) most resembles. There are two main groups: germinal-centre B-cell (GCB) and activated B-cell (ABC), also called non-GCB. The distinction is made using gene-expression profiling, or more commonly in routine practice a panel of immunohistochemistry markers (such as CD10, BCL6 and MUM1) read through an algorithm. Cell of origin is a recognised prognostic feature — GCB and non-GCB DLBCL tend to behave differently — so it is reported on many DLBCL pathology reports. Understanding your cell-of-origin result is part of how doctors identify your exact lymphoma subtype, which then shapes the treatment plan discussed at the tumour board.
A "double-hit" (or triple-hit) lymphoma is an aggressive B-cell lymphoma that carries a rearrangement of the MYC gene together with a rearrangement of BCL2 and/or BCL6. It is now classified as high-grade B-cell lymphoma with these rearrangements. The test used is FISH (fluorescence in-situ hybridisation), which detects these specific genetic breaks on the biopsy tissue. Because a double-hit result changes how aggressively the disease is treated, NCCN recommends FISH for MYC, BCL2 and BCL6 in large B-cell lymphomas. You can read more on our dedicated double-hit / high-grade B-cell lymphoma page. At CION this testing is arranged as part of the diagnostic work-up.
The exact panel depends on the suspected subtype, but common markers include surface proteins such as CD20 (a hallmark of most B-cell lymphomas), CD3 (T-cells), CD30 and CD15 (important in Hodgkin lymphoma), CD10, BCL6 and MUM1 (used for cell of origin in DLBCL), and proliferation markers like Ki-67. Genetic tests then look for rearrangements of MYC, BCL2 and BCL6. These are detected through immunohistochemistry, flow cytometry and FISH. Together they build a molecular fingerprint of the lymphoma that guides diagnosis, prognosis and treatment intensity. The panel is always chosen by the pathologist based on the clinical picture and the appearance of the cells.
Molecular and genetic tests are run on the lymphoma tissue itself, so they need an adequate sample. This is why lymphoma is best diagnosed on a whole lymph node rather than a tiny fragment — an excisional biopsy of the whole node preserves the architecture and gives enough tissue for the full marker panel. Where surgery is not practical, a core needle biopsy may be used, and a bone marrow biopsy is sometimes needed to check for marrow involvement. A fine-needle aspirate alone is usually not enough for molecular testing. At CION the biopsy is coordinated so the right tissue is collected the first time.
Often, yes. Molecular results confirm the precise subtype and reveal biological features that influence how the disease should be treated — for example, a double-hit rearrangement typically prompts a more intensive approach, while cell-of-origin and marker results (such as CD20 positivity, which makes a lymphoma suitable for anti-CD20 antibody therapy) inform the drug class chosen. CION does not decide treatment on a marker alone: every result is reviewed by a multidisciplinary tumour board alongside your stage, LDH level and overall health. Specific regimens are discussed on our Lymphoma Treatment in Hyderabad page rather than here, so this page stays focused on the testing itself.
Basic immunohistochemistry markers are often available within a few days of the biopsy, while FISH and gene-expression studies can take longer — usually one to two weeks — because they involve specialised laboratory processing. It can feel like a frustrating wait after a lymphoma diagnosis, but getting the molecular picture right before starting treatment is worth it: NCCN and ESMO both recommend that the relevant molecular information be available to guide the plan. At CION, testing is arranged promptly on your biopsy, urgent cases are flagged to the laboratory, and your team explains each result as it arrives. If you would like your existing reports reviewed, you can book a free consultation.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.